Cerecor (NASDAQ: CERC) is one of 531 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Cerecor to related companies based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, valuation and institutional ownership.

Analyst Ratings

This is a summary of recent ratings for Cerecor and its peers, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cerecor 0 0 0 0 N/A
Cerecor Competitors 3866 11256 25494 850 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 65.04%. Given Cerecor’s peers higher probable upside, analysts clearly believe Cerecor has less favorable growth aspects than its peers.


This table compares Cerecor and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cerecor -241.29% -75.94% -29.05%
Cerecor Competitors -1,917.64% -92.21% -26.21%

Institutional & Insider Ownership

44.5% of Cerecor shares are held by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 80.2% of Cerecor shares are held by company insiders. Comparatively, 15.0% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cerecor and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cerecor $27.81 million $11.86 million 8.12
Cerecor Competitors $2.18 billion $164.73 million -1.74

Cerecor’s peers have higher revenue and earnings than Cerecor. Cerecor is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Cerecor has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Cerecor’s peers have a beta of 1.16, meaning that their average stock price is 16% more volatile than the S&P 500.

Cerecor Company Profile

Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation. It also offers Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension; and Flexichamber. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and two preclinical stage development candidates, CERC-406 and CERC-425 potential for the treatment of motoric and non-motoric symptoms of Parkinson's disease, as well as other psychiatric and neurological conditions. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Baltimore, Maryland.

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.